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Abstract 
Ghrelin gene generates several variants that regulate multiple pathophysiological functions, including 
tumor-related processes. In1-ghrelin is a splicing variant that was previously shown to be overexpressed 
in breast cancer (BCa), where it correlated with proliferation markers; however, its possible association 
with clinical outcome of BCa patients and underlying mechanisms are still unknown. To address this 
issue, expression levels and clinical associations of In1-ghrelin were analysed in a cohort of 117 BCa 
samples. Additionally, a battery of cellular and molecular assays were implemented using two BCa cell 
lines (MCF-7 and MDA-MB-231), wherein the role of In1-ghrelin on proliferation, migration, 
dedifferentiation and signaling pathways was explored. The results generated revealed that high 
expression of In1-ghrelin in BCa samples was associated with lymph node metastasis and reduced 
disease-free survival. Indeed, In1-ghrelin overexpression stimulated proliferation and migration in 
MCF-7 and MDA-MB-231 cells. Similar results were found by treating MDA-MB-231 and MCF-7 
with In1-ghrelin-derived peptides. Conversely, In1-ghrelin silencing decreased proliferation and 
migration capacities of MDA-MB-231. Furthermore, In1-ghrelin (but not ghrelin) overexpression 
increased the capacity to form mammospheres in both cell lines. These effects could be associated with 
activation of MAPK-ERK, Jag1/Notch, Wnt/β-catenin, and/or TGF-β1 pathways. Altogether, our data 
indicate that In1-ghrelin could play relevant functional roles in the regulation of BCa development and 
progression, and may provide insights to identify novel biomarkers and new therapeutic approaches for 
this pathology. 
Implication: In1-ghrelin could represent a novel biomarker and provide novel therapeutic opportunities 
in BCa as it was associated with lymph node metastasis and reduced disease-free survival. 
4 
Introduction 
Breast cancer (BCa) is the most frequently diagnosed malignancy in women [1]. Although mortality has 
been diminishing over the last years, BCa is still the second leading-cause of cancer-related deaths in 
women [1]. The search for common molecular markers among the vast genetic heterogeneity in the 
different BCa types [2], which could facilitate the discovery of new drug targets and help to develop 
more efficient diagnostic, prognostic and therapeutic markers, has led to the identification of aberrant 
alternative splicing events as a common hallmark in cancer development and progression [3, 4]. Indeed, 
appearance and/or overexpression of certain splicing variants in tumor cells has been associated with 
increased drug resistance [5], escape from the immune system [6] or increased malignancy features and 
metastatic potential [3]. 
In this scenario, ghrelin gene has emerged as a complex and tightly regulated system, relevant in tumor 
pathologies, and with potential value as molecular marker and/or therapeutic target [7]. Thus, besides 
the known actions of native ghrelin as a truly pleiotropic hormone, the ghrelin gene itself comprises an 
intricate system [8], which includes the existence of several splicing variants [9], the proteolytic 
processing of pre-pro-peptides to yield different hormones [10], or specific post-transcriptional 
modification, such as acylation, that generates the best-known biologically-active peptide, acyl-ghrelin. 
Interestingly, the presence of acyl-ghrelin and its canonical receptor GHS-R1a has been reported in 
several endocrine and non-endocrine tumors [11], where their function varies from modulation of 
growth hormone expression and secretion in pituitary tumors, to proliferative effects on prostate [12], 
breast [13] or follicular thyroid carcinoma [14] cell lines. In spite of these observations, the actual 
significance of ghrelin system in tumor pathologies is poorly understood, likely due to controversial 
results from studies showing that ghrelin may be a good prognostic marker in BCa [15], but may inhibit 
proliferation [16] or display a biphasic effect in prostate cancer cell lines [17]. 
Additionaly, elucidation of the precise biological significance of the ghrelin system has been hampered 
by the intrinsic complexity of the ghrelin peptide/receptor family [8]. Indeed, over the last years, several 
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splicing variants of the ghrelin and ghrelin receptor genes have been identified and associated with 
several human pathologies [8]. Among the ghrelin-gene splicing products, special attention has been 
focused on the In1-ghrelin variant [18], a recently discovered splicing-derived variant generated by the 
retention of the intron 1 [18]. The In1-ghrelin variant is overexpressed in different tumor pathologies, 
such as BCa [18], pituitary [19] and neuroendocrine tumors [20]. Moreover, its expression seems to be 
associate with tumor malignancy, since In1-ghrelin mRNA expression levels correlate with proliferation 
markers, like Ki-67 and cyclin D3 in BCa [18], and In1-ghrelin overexpression and/or treatment induces 
higher cell viability and inhibition of apoptotic processes [19, 20], and also increases hormone 
hypersecretion from pituitary and neuroendocrine tumors [19, 20]. Altogether, these data support a 
plausible relevance of the In1-ghrelin splicing variant in tumor processes, and suggest the necessity to 
implement further studies to clarify the specific functions and putative clinical implications of this 
splicing variant in relevant tumor pathologies, such as BCa. Accordingly, the aim of this study was to 
explore the putative clinical implications of the expression of this variant in samples from a well-
characterized human BCa cohort as well as to determine the functional and mechanistic implications of 
In1-ghrelin on two representative BCa cell lines. 
6 
Material and methods 
Human samples 
A total of 117 infiltrating grade 3 ductal (IDC) BCa samples acquired from the archives of the 
Pathology Department of MD Anderson Cancer Center (Madrid, Spain) and previously described  in 
[21, 22] were included. Patients underwent surgery between 2003 and 2004 with a mean age at surgery 
of 54.9years (range, 27-79years). According to the TNM Classification staging, 48 of the tumors were 
stage I, 34 were stage II, and 35 were stage III-IV. Relevant clinical data of the patients are provided in 
Supplemental Table 1. This study was performed following standard ethical procedures of the Spanish 
regulation (Ley de Investigación Orgánica Biomédica, 14 July 2007) and was approved by the ethic 
committee of MD Anderson Cancer Center, Madrid, Spain. 
Cell lines 
Invasive ER-negative (MDA-MB-231) and non-invasive ER-positive (MCF-7) BCa cell lines (ATCC, 
Barcelona, Spain) were validated by analysis of STRs (GenePrint® 10 System, Promega, Barcelona, 
Spain) and checked for mycoplasma contamination by PCR [23]. Cells were cultured in DMEM with 
4,5g glucose (Lonza, Basel, Switzerland), 2mM L-Glutamine (Thermo Scientific, Wilmington, NC, 
USA), 10% FBS (Sigma, Barcelona, Spain) and 0,2% gentamicin/amphotericin (Thermo Scientific) and 
maintained at 37ºC and 5% CO2. 
Plasmids, siRNAs and transfection 
The expression vector pCDNA3.1 (Thermo Scientific) was used for cloning and overexpression. Details 
regarding In1-ghrelin cloning have been previously reported [18]; while ghrelin sequence was 
purchased from PlasmidID (Harvard Medical School, Boston, MA) and subcloned into pCDNA3.1. 
Cells were transfected using Lipofectamine-2000 (Gibco, Barcelona, Spain) following manufacturer’s 
instructions and stable-transfected cells were selected by addition of geneticin (1%; Gibco). To generate 
monoclonal cell lines, single clones were selected by limiting dilutions and validated by quantitative 
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real-time PCR (qPCR). Stably-transfected cells with empty pCDNA3.1 (control) were used as a 
negative control. 
In1-ghrelin knock-down on MDA-MB-231 cells, which exhibited a basal, appreciable endogenous 
expression of In1-ghrelin, was carried out by using two custom-designed In1-ghrelin specific siRNAs 
[siRNA-1 (5’-GAGTCCTAAACAGACTGTT-3’) already published [19] and siRNA-2 (5’-
CACUGUUUCUGGAAGGACATT-3’)] and compared with cells treated with a commercial control-
siRNA (Silencer Select Negative Control No.1 siRNA, Thermo Scientific). Specifically, cells were 
transfected with these siRNAs (100nM) using Lipofectamine RNAiMAX (Gibco) and following 
manufacturer’s instructions. siRNA effectiveness was validated by qPCR. All studies were developed 
two days after siRNA transfection, in identical condition to plasmid-transfected cells. 
Peptides 
Human acylated-ghrelin was commercially available (SC1357, PolyPeptide Laboratories, Limhamn, 
Sweden), while In1-ghrelin-derived acylated peptides were synthesized in collaboration with IPSEN 
Bioscience (Cambridge, MA, USA). Although the endogenous In1-ghrelin derived mature peptides have 
not yet been purified, pre-pro-In1-ghrelin precursor exhibits well-recognized target sites for protein-
convertases, suggesting a proteolytic processing. As previously reported, In1-ghrelin precursor 
processing could generate 19-aa or 40-aa long peptides (named In1-19: GSSFLSPEHQRVQVRPPHK 
and In1-40: GSSFLSPEHQRVQVRPPHKAPHVVPALPLSNQLCDLEQQR), which share with native 
ghrelin the initial 13-aa, including the acylation site at Ser3 (for details, see Supplemental Figure 2). 
Thus, In1-19 and In1-40 peptides were synthesized as their acylated forms [19]. Paclitaxel and IGF1 
were purchased from Sigma-Aldrich. 
RNA isolation and qPCR 
RNA extraction, quantification and reverse-transcription, as well as the development, validation and 
application of qPCR to measure the expression levels of different human transcripts, have been 
previously reported by our group [18, 24-27]. Briefly, total RNA was extracted from cell lines and 
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paraffin-embedded BCa samples with Trizol (Thermo Scientific) following manufacturer’s protocol and 
subsequently treated with DNase (Promega). Total RNA concentration and purity was assessed using 
Nanodrop-2000 spectrophotometer (Thermo Scientific), and subsequently retro-transcribed using 
random hexamer primers and cDNA First Strand Synthesis kit (Thermo Scientific). Complementary 
DNA derived from cell lines and from paraffin-embedded BCa samples were amplified by qPCR using 
Brilliant III SYBR Green Master Mix in the Stratagene Mx3000p instrument (Agilent, La Jolla, CA, 
USA) [24-26]. Thermal profile consisted of an initial step at 95°C for 3 minutes, followed by 40 cycles 
of denaturation (95°C for 30 seconds) and annealing/extension (60°C for 30 seconds); and finally, a 
dissociation cycle to verify that only one product was amplified. Primer details are presented in 
Supplemental Table 2. The expression level (copy-number) of each transcript was adjusted by the most 
appropriate housekeeping gene(s) selected through Genorm software analysis. Specifically, BCa 
samples were normalized using ACTB expression levels, while cell lines data were normalized by a 
normalization factor (NF) calculated from HPRT and GAPDH expression levels. 
In vitro cell proliferation 
Cell proliferation was evaluated in stably transfected cells using Alamar-Blue reagent (Thermo 
Scientific) as previously reported [18, 28]. Briefly, 3000 cells/well were plated in 96-wells plates and 
the day of measurement, cells were incubated for 4 hours in 10% Alamar-Blue blue/serum free-DMEM 
and then, Alamar-Blue reduction was measured in a FlexStation system plate reader, exciting at 560 nm 
and reading at 590 nm. Alternatively, we implemented proliferation measurements by MTT assay 
(Sigma-Aldrich). Briefly, 3000 cells/well were plated in 96-wells plates and the day of measurement, 
100l of MTT diluted in d-PBS (Sigma-Aldrich) were added to the cells and then incubated 3 hours at 
37C. Subsequently, cells were detached with lysis buffer (10% SDS, 0,56% glacial acetic acid in 
DMSO) and absorbance measured using the FlexStation system plate reader, at 570nm. In all instances, 
cells were plated per quadruplicate and all assays were repeated a minimum of five times. Results are 
expressed as percentage vs. control cells. 
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Migration Assay 
The ability of cells to migrate in response to In1-ghrelin or ghrelin overexpression or treatment was 
evaluated by wound healing technique as previously reported [28]. Briefly, cells were plated at sub-
confluence in 12-wells plates. The wound was made using a 200µl sterile pipette tip on confluent cells. 
Then, cells were incubated for 24h in medium without FBS to prevent cell proliferation. Wound healing 
was calculated as the area recovered after 24hours. At least, four experiments were performed in 
tripiclates on independent days, in which three-four random pictures along the wound were acquired. 
Results are expressed as percentage vs. control. In treatment assays, ghrelin, In1-ghrelin peptides, IGF 
and paclitaxel (positive and negative controls) were added with the culture medium at time 0. 
Mammospheres formation assays 
The ability to form mammospheres in response to In1-ghrelin or ghrelin overexpression or treatment 
was evaluated by mammospheres formation assay [29]. Briefly, 6.000-10.000 cells were seeded in 
pHEMA (Sigma-Aldrich) pretreated 6-wells plates using phenol red-free DMEM/F12 medium (Gibco) 
supplemented with rEGF (20ng/ml; Sigma-Aldrich) and B27 supplement without vitamin-A (Thermo 
Scientific). Then, cells were incubated for 7 days at 37ºC and 5%CO2 and, subsequently, 
mammospheres were counted. In treatment assays, peptide was added to the medium at day zero and 
refreshed each two days. To analyze mammospheres size, they were collected, disaggregated with 
trypsin/EDTA (Gibco), passed through a 25G needle and finally the number of individual cells was 
counted using a Neubauer chamber. Average number of cells was adjusted by the number of 
mammospheres as a representation of the size of each mammospheres. 
Western Blot 
Cells were cultured to subconfluence in 6-well plates and lysed in pre-warmed SDS-DTT buffer 
(62,5mM Tris-HCl, 2% SDS, 20% glicerol, 100mM DTT) followed by sonication for 10 sec and boiling 
for 5min at 95º C. Proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes 
(Millipore). Membranes were blocked with 5% non-fat dry milk in Tris-buffered saline/0.05% Tween 
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20 and incubated with the primary antibodies for ERK1/2 (Santa Cruz, Dallas, TX, USA), phospho-
ERK1/2, phospho-Akt, or Akt (Cell Signaling, Beverly, MA) and the appropriate secondary antibody 
(Anti Rabbit IgG HRP-linked, Cell Signaling). Proteins were developed using ECL-2 (GE Healthcare, 
Madrid, Spain) following manufacturer’s instructions. Densitometric analysis of the bands was carried 
out with ImageJ software. The relative phospho-ERK and phospho-Akt values were obtained from 
normalization of phospho-ERK1/2 or phospho-Akt values against the total ERK1/2 or Akt values, 
respectively. 
Statistical analysis 
For the analysis of human breast carcinoma data, samples were categorized as low, moderate and high 
In1-ghrelin levels according to quartile In1-ghrelin expression levels (0-50% as low, 50-75% as 
moderate and 75-100% as high). Significant correlations between categorized In1-ghrelin mRNA 
expression, presence of metastasis and disease-free survival were studied using Chi-square and Long-
rank-p-value methods. For in vitro experiments, data are expressed as mean±SEM obtained. Data were 
evaluated for heterogeneity of variance using the Kolmogorov–Smirnov test. Statistical analysis was 
carried out using one-way ANOVA followed by Dunnett’s test. Statistical analyses were carried out 
with GraphPad Prism 6 (La Jolla, CA, USA) and SPSS 17.0 (IBM). P-values smaller than 0.05 were 
considered statistically significant. 
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Results 
In1-ghrelin expression correlated with lymph node metastasis and lower disease-free survival in BCa 
patients 
To ascertain the putative clinical significance of In1-ghrelin in BCa patients, we evaluated the 
expression of In1-ghrelin in a cohort of 117 BCa samples, and explored its association with malignancy-
associated features, such as lymph node metastasis and disease-free survival. To accomplish this, 
samples were categorized as low, moderate and high In1-ghrelin expression according to quartile In1-
ghrelin expression levels (0-50% as low, 50-75% as moderate and 75-100% as high) (Figure 1A-B). 
This analysis showed a remarkable association (p=0.001) between In1-ghrelin expression and lymph 
node metastasis, wherein patients with high In1-ghrelin expression levels presented more lymph node 
metastasis (Figure 1C). Moreover, BCa patients with high expression of In1-ghrelin presented 
significantly (p<0.001) lower disease-free survival than those with low or moderate In1-ghrelin 
expression (Figure 1D), while no significant differences were observed between patients with low or 
moderate In1-ghrelin expression (Figure 1D). Remarkably, the same analysis implemented with the 
canonical variant ghrelin, or with the ratio between In1-ghrelin and ghrelin, did not show any significant 
association with lymph node metastasis or disease-free survival (data not shown). 
In1-ghrelin increased cell proliferation and migration. 
In1-ghrelin expression levels were low in non-invasive MCF-7 cell line but considerably higher in 
invasive MDA-MB-231; while ghrelin was almost undetectable in both cell lines (Supplemental Table 
3). As expected, stably-transfected In1-ghrelin cells exhibited elevated levels of In1-ghrelin by qPCR, 
with no changes in ghrelin expression; whereas, stably-transfected ghrelin cells exhibited elevated levels 
of ghrelin without changes in In1-ghrelin expression (Figure 2A). 
In1-ghrelin overexpressing MDA-MB-231 and MCF-7 cells exhibited a significantly increased cell 
proliferation rate compared to control cells by Alamar-Blue assay (MDA-MB-231: 113% and 117% at 
24 and 72 hours respectively; MCF-7: 151%, 159% and 185% at 24, 48 and 72 hours respectively) 
(Figure 2B). Additionally, overexpression of ghrelin increased cell proliferation after 48-72h in MDA-
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MB-231 (117% at both 24 and 72 hours), but not in MCF-7 (Figure 2B). These results were further 
confirmed using MTT assay, which generated similar results (Supplemental Figure 1), in that In1-19 
(120% and 119% at 48 and 72 hours respectively), In1-40 (122%, 124% and 116% at 24, 48 and 72 
hours respectively) and native ghrelin (124% at 72 hours) increased proliferation in MDA-MB-231 cells 
compared to vehicle, but only In1-ghrelin derived peptides stimulated proliferation in MCF-7 (113% 
and 115% at 72 hours for In1-19 and In1-40 respectively) (Figure 2C). As expected, Paclitaxel 
treatment (used as a control for cell proliferation and migration inhibition) induced a clear decrease in 
cell proliferation in both, MDA-MB-231 (72%, 50% and 37% at 24, 48 and 72 hours, respectively, 
compared with vehicle-treated cells) and MCF-7 (86%, 75% and 57% at 24, 48 and 72 hours, 
respectively, compared with vehicle-treated cells) cells lines; while IGF-I (a classical stimulator of 
proliferation and migration) significantly increased proliferation rate at 48 and 72 hours in MDA-MB-
231 (119% and 120% respectively) and at 72 hours in MCF-7 cells (112%), which suggest a similar 
stimulatory effect of In1-ghrelin peptides than IGF-I in these cell lines. 
In general, these results robustly and consistently demonstrate that the presence of In1-ghrelin, or its 
derived peptides, is able to increase the proliferation rate of breast cancer cells, although the extent of 
the induction is not exactly the same in all the experimental conditions. However, the particular 
differences observed between MDA-MB-231 and MCF-7 cells could be related to the actual difference 
in basal expression of In1-ghrelin variant between both cell lines; indeed, MDA-MB-231 cells present a 
higher basal expression of In1-ghrelin than MCF-7, which may suggest that endogenous In1-ghrelin in 
MDA-MB-231 cells could be exerting a role by increasing basal proliferation so that additional 
expression of this splicing variant presents a lower effect than in cells with a lower basal expression, as 
is the case of MCF-7 cells. Alternatively, it is also possible that the higher basal proliferation rate of 
MDA-MB-231 compared with MCF-7 could have an effect in the observed differences. On the other 
hand, the differences between overexpression and peptide treatment effects could be related to the 
different dynamics of both types of experiments in that treatment with peptides commonly evoke more 
acute, short-lived effect; whereas, overexpression experiments seem to maintain higher levels over time, 
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and therefore, likely provides a better model to observe an effect on cell proliferation in response to an 
overexposure. 
In1-ghrelin overexpressing cells exhibited increased migration ability (Figure 3A), whereas ghrelin-
overexpressing cells did not show any difference in migration capacity compared with control cells 
(Figure 3A). Similarly, non-transfected cells exhibited higher migration capacity when treated with In1-
ghrelin peptides compared with vehicle-treated cells (Figure 3A). Interestingly, acyl-ghrelin treatment 
only increased migration capacity significantly in MDA-MB-231 cells (Figure 3A). It should be noted 
that both, stimulatory and inhibitory, controls (IGF-I and paclitaxel) exerted the expected results in the 
migration ability of both cell lines.  Moreover, In1-ghrelin, but not ghrelin, overexpression induced an 
increase in basal ERK phosphorylation with no changes in AKT phosphorylation (Figure 4). 
In1-ghrelin down-regulation decreased cell proliferation and migration 
Two different In1-ghrelin specific siRNAs that successfully reduced In1-ghrelin mRNA expression 
(Figure 3B) were deployed to analyze proliferation rate and migration capacity. In1-ghrelin inhibition 
induced a clear decrease in migration and proliferation rates compared with control siRNA transfected 
cells (Figures 3C-D). Similar results were obtained with both independent siRNAs. 
In1-ghrelin overexpression increased mammosphere formation 
In1-ghrelin but not ghrelin overexpression induced a marked increase in the number of mammospheres 
in both cell lines (Figure 5A), and, in the case of MDA-MB-231 cell line, in mammospheres size 
(Figure 5B), as compared with control and ghrelin-transfected cells. Consistently, cells treated during 7 
days with In1-ghrelin derived peptides exhibited increased capacity to form mammospheres compared 
with vehicle- and ghrelin-treated cells (Figure 5A). Although it is not clear the reason why In1-ghrelin 
overexpression only increases mammosphere size (cell content) in MDA-MB-231 cells (which could be 
due to intrinsic cell line-specific factors, including the own endogenous In1-ghrelin expression), these 
results demonstrate that In1-ghrelin overexposition has a profound effect on mammosphere formation. 
14 
To explore the molecular basis of these In1-ghrelin-induced changes, the expression pattern of key 
genes of three signaling pathways related to dedifferentiation (TGF-β1 [30], Notch [31] and Wnt/β-
catenin [32]) was explored. Overexpression of ghrelin and In1-ghrelin increased TGF-1 expression. 
We also measured JAG1, a Notch pathway ligand, and -catenin (CTNNB1), a Wnt pathway effector 
protein, which has been clearly correlated with dedifferentiation processes [33, 34]. JAG1 showed 
elevated mRNA levels in In1-ghrelin and ghrelin transfected cells (Figure 6). Interestingly, -catenin 
showed increased mRNA levels in cell lines overexpressing In1-ghrelin, but not ghrelin (Figure 6). 
Finally, we also explored the expression levels of the canonical receptor for native ghrelin, GHS-R1a, as 
well as its truncated form GHS-R1b, and found that both were absent or close to the detection limit 
(GHS-R1a: Ct = 37,0 – 37,1 in MDA-MB-231 and MCF-7 cell lines and GHS-R1b: Ct = 35,2 – 33,4 in 
MDA-MB-231 and MCF-7 cell lines, respectively). 
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Discussion 
Aberrant alternative splicing events have been observed in several cancer types and are currently 
considered as an emerging cancer hallmark [4, 35]. These processes promote the aberrant appearance of 
novel mRNA and protein variants, distinct from those present in healthy tissues [36], and whose  
expression is often associated with malignant features and poor prognosis. Indeed, the 
pathophysiological role of these aberrant splicing variants span from the promotion of apoptosis [37] or 
immune system escape [38], to increased malignancy features, such as proliferation, migration, invasion 
or metastatic ability [39, 40].  In this scenario, previous studies have demonstrated that expression of the 
splicing variant In1-ghrelin is tightly linked to enhanced malignancy and/or aggressiveness features in 
human BCa [18], and in pituitary [19] and neuroendocrine [20] tumors; however, the exact functions of 
In1-ghrelin splicing variant in BCa pathophysiology is yet to be determined. 
In the present study, we have demonstrated for first time a relevant association between high In1-ghrelin 
expression levels and lymph node metastasis. Indeed, patients with BCa samples categorized as bearing 
low levels or no expression of In1-ghrelin presented with less metastasis than those whose samples 
showed a high level of In1-ghrelin expression.  Moreover, 10-year flollow-up studies on these patients 
revealed that high expression of In1-ghrelin strongly correlated with increased recurrence or de novo 
tumor appearance, demonstrating a relevant implication of this splicing variant on the clinical outcome 
of BCa patients and suggesting its putative value as prognostic marker and/or therapeutic target in BCa. 
Mechanistically, proliferation and migration rates were increased in In1-ghrelin overexpressing MDA-
MB-231 and MCF-7 cells and in response to In1-ghrelin derived peptides, which is in line with previous 
results [18]. Indeed, In-ghrelin overexpression and treatment increases malignancy features in cultured 
pituitary and neuroendocrine tumor cells [19, 20], thereby providing a plausible rationale to suggest that 
In1-ghrelin may play a common, malignancy-linked role among different cancer types. Herein, In1-
ghrelin overexpression was accompanied by changes in basal phosphorylation of the crucial, tumor-
associated signaling pathway MAPK/ERK [41], which may explain the observed changes in cellular 
proliferation and migration. Importantly, these results were further corroborated by In1-ghrelin 
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downregulation using two independent siRNAs in MDA-MB-231 cells, reinforcing the notion that 
counteracting In1-ghrelin may confer a therapeutic benefit. 
The precise role of the ghrelin system in cancer is still a matter of controversy [7, 15-17], likely due to 
the diversity of components of this complex system. In this context, in the present study, side-by-side 
comparison of ghrelin and In-1ghrelin peptides revealed that although both induced changes in 
proliferation and migration, the fact that only In1-ghrelin altered the ERK signaling pathway, suggests 
that the two splicing variants of the ghrelin gene could be exerting their functions by different receptors 
and/or signaling cascades. Surprisingly, MDA-MB-231 and MCF-7 cells lines did not show relevant 
expression levels of the canonical ghrelin receptors GHS-R1a, or its spliced variant GHS-R1b, which 
would imply that the observed changes may be mediated by as of yet unknown, and likely distinct 
receptors. 
Finally, the clinical findings found herein compare well with the higher number of CSCs induced by 
In1-ghrelin overexposure in both tumor cell lines, since CSCs have been associated with tumor relapse  
and metastatic potential [42]. Particularly, the in vitro results shown herein indicate a clear increase in 
mammosphere number and, in MDA-MB-231 cells, mammosphere size, when the cells are transfected 
with In1-ghrelin or treated with In1-ghrelin peptides, but not with native ghrelin. These results further 
demonstrate a clear capacity of the In1-ghrelin variant to increase the ability of MDA-MB-231 and 
MCF-7 cells to dedifferentiate, and to stimulate the mammosphere proliferation rate of MDA-MB-231 
cells. Therefore, with the aim of further elucidating the molecular mechanisms underlying the 
association between In1-ghrelin and the dedifferentiation processes, we determined the expression 
levels of several candidate genes that have been shown to be involved in signaling pathways associated 
with cell plasticity and CSCs in previous studies [33, 43]. In particular, these tumor processes are tightly 
associated with activation of certain signaling pathways such as TGF-β1 [30], Notch [31] and Wnt/β-
catenin [32], which have been shown to crosstalk in order to modulate EMT and CSCs biology [44]. 
Interestingly, we discovered that In1-ghrelin overexpression induced a clear up-regulation of TGF-1 
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expression, which was particularly marked in MDA-MB-231 cells. In addition, In1-ghrelin 
overexpression increased mRNA levels of JAG1, one of the main activators of Notch signaling [45], 
and those of β-catenin, which was especially evident in MCF-7 cells, and which would explain the clear 
changes induced by In1-ghrelin in forming mammospheres. It is interesting to note that In1-ghrelin 
overexpression induced a similar, albeit not completely identical change in the expression levels of 
differentiation-related genes in both cell lines. Specifically, In1-ghrelin overexpression in MDA-MB-
231 mainly altered the expression levels of TGF-ß1, while it only moderately changed ß-catenin and 
JAG1 expression levels. Contrarily, In1-ghrelin overexpression in MCF-7 cells alters moderately TGF-
β1 mRNA expression but strongly increase the expression levels of JAG1. These data, together with the 
fact that ghrelin overexpression induced distinct, though less pronounced, changes in the expression of 
the mentioned signaling pathways, suggests that In1-ghrelin triggers specific changes in TGF-β1, Notch 
and Wnt/β-catenin signaling pathways to modulate cell plasticity and CSCs biology, which could be 
BCa cell line-dependent. 
The present results demonstrate that the In1-ghrelin splicing variant may have relevant clinical 
implications, in that In1-ghrelin may contribute to human tumor progression, metastasis, and relapse, as 
indicated by the data collected from patient samples. The cellular and molecular approaches 
demonstrated that In1-ghrelin enhances the malignant features of two BCa derived cell lines, MDA-
MB-231 and MCF-7.  Moreover, we provide plausible key mechanisms of action underlying the In1-
ghrelin effects; specifically, activation of the MAPK-ERK, Jag1/Notch, Wnt/-catenin and/or TGF-1 
signaling pathways. The fact that the effects of In1-ghrelin are different from those exerted by the 
canonical native variant of the ghrelin gene, ghrelin, underscore the promising value of In1-ghrelin as a 
biomarker and therapeutic target in BCa treatment and diagnosis. 
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Figure Legends 
Figure 1. In1-ghrelin expression levels are associated with lymph node metastasis and lower 
disease-free survival in breast cancer patients. A) Expression levels of In1-ghrelin (adjusted by 
ACTB) in the 117 grade 3 breast carcinomas and their classification as low, medium or high In1-ghrelin 
mRNA levels. B) Average expression levels of In1-ghrelin (adjusted by ACTB) in the breast carcinoma 
samples within each group (low, medium or high In1-ghrelin mRNA levels). Samples were categorized 
as low, moderate and high In1-ghrelin expression according to quartile In1-ghrelin expression levels (0-
50% as low, 50-75% as moderate and 75-100% as high). C) Association between the presence of In1-
ghrelin and lymph node metastasis in breast carcinoma samples. Data, obtained from a frequency table, 
showed an association between In1-ghrelin expression and lymph node metastasis. D) Kaplan-Meier 
plots showing the association of increased In1-ghrelin mRNA expression and disease-free survival in 
breast carcinoma series. Significant correlation was studied using a Chi-square and Long-rank-p-value 
methods. Asterisks (***, p<0.001) indicate significant differences between groups by One-way 
ANOVA followed by Dunnett’s test. 
Figure 2. In1-ghrelin stimulated cell proliferation in breast cancer cell lines. A) Validation of In1-
ghrelin and ghrelin overexpression by qPCR in MDA-MB-231 and MCF-7 stably transfected cells. 
Copy number are normalized by a normalization factor (NF) and data are showed as percentage of 
control cells (n=10 different cell preparations). B) Proliferation rates determined by Alamar blue 
technique (n=6 for each cell line). C) Proliferation rate assayed by Alamar blue after treatment with In1-
ghrelin and ghrelin peptides (n=8-7 in MDA-MB-231 and MCF-7 cell lines, respectively). Values 
represent means ± SEM. Asterisks (*, p<0.05; **, p<0.01; ***, p<0.001) indicate significant differences 
between groups by One-way ANOVA followed by Dunnett’s test. 
Figure 3. In1-ghrelin stimulated migration rate in breast cancer cell lines and its downregulation 
decreased proliferation rate and migration in MDA-MB-231 cells. A) Migration ability was 
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determined by wound healing technique in overexpressing (n=4-6 in MDA-MB-231 and MCF-7 cell 
lines, respectively) and treated (n=4-5 in MDA-MB-231 and MCF-7 cell lines, respectively) cells. B) 
Validation of In1-ghrelin downregulation by siRNAs transfections expressed as percentage of control 
siRNA expression levels (n=6-4 in siRNA-1 and siRNA-2, respectively). C) Migration ability analysis 
by wound healing technique (n=3-4 in siRNA-1 and siRNA-2, respectively) represented as percentage 
of control siRNA-transfected cell migration, and a representative picture of each transfected cells at 0 
and 24 hours. D) Proliferation rates in cells transfected with specific siRNAs compared with control 
siRNA-transfected cells (n=5-3 in siRNA-1 and siRNA-2, respectively). Values represent means ± 
SEM. Asterisks above each point (*, p<0.05; **, p<0.01; ***, p<0.001) indicate significant differences 
between groups by One-way ANOVA followed by Dunnett’s test 
Figure 4. In1-ghrelin stimulated ERK phosphorylation in MDA-MB-231 cells. Basal ERK (n=5) 
and AKT (n=4) phosphorylation in In1-ghrelin and ghrelin transfected MDA-MB-231 cell lines 
compared with Control. Values represent means ± SEM. Asterisks above each point (*, p<0.05) indicate 
significant differences between groups by One-way ANOVA followed by Dunnett’s test. pERK states 
for phospho-ERK while pAkt states for phospho-Akt. 
Figure 5. In1-ghrelin overexposure increased mammospheres formation and size. A) Percentage of 
mammospheres in transfected (n=5-3 in MDA-MB-231 and MCF-7 cells, respectively) and treated 
(n=4) cells compared with control and vehicle treated cells, respectively. B) Average number of cells by 
mammosphere in each transfected cell lines (n=3). Values represent means ± SEM. Asterisks (*, 
p<0.05) indicate significant differences between groups by One-way ANOVA followed by Dunnett’s 
test. 
Figure 6. In1-ghrelin and ghrelin altered mRNA expression levels of dedifferentiation related 
genes. mRNA expression levels of b-Catenin (CTNNB1), Jagged1 (JAG1), and Tumor Growth Factor-
b1 (TGF-b1) are showed as a percentage of mock cells expression (n=10 independent cell preparations). 
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Values represent means ± SEM. Asterisks (*, p<0.05; **, p<0.01; ***, p<0.001) indicate significant 
differences between groups by One-way ANOVA. 






